周兆才｜Zhou, Zhaocai

center for excellence in molecular cell science, cas特聘教授

H指数:0

被引数:0

浏览量:0

个人简介

"国家杰青、国家重点研发计划首席科学家\n国家二级教授、复旦大学特聘教授、复旦大学附属中山医院双聘教授、复旦大学曹娥江转化医学创新中心副院长、复旦大学学位委员会委员及生物学分委会主席、复旦大学生命科学学院学术委员会委员、复杂性状的遗传调控全国重点实验室研究组长。\n2004年博士毕业于中国科学技术大学，随后赴美国费城UPenn药学院从事博士后研究（师从抗癌药物Herceptin研发先驱Mark I. Greene教授）。2009年中国科学院百人计划引进回国，历任生物化学与细胞生物学研究所、分子生物学国家重点实验室、细胞生物学国家重点实验室、分子细胞科学卓越创新中心特聘研究员（中科院战略性科技先导专项资助）。2014年百人计划终期评估优秀，同年被授予中科院杰出青年科技创新人才称号，任中科院与高校联合交叉创新团队负责人。2017年获国家自然科学基金委医学部杰青资助。2020年加入复旦大学。担任Nat Cell Biol、Nat Chem Biol、J Clin Invest、J Exp Med、Nat Commun、Cell Res、Cell Rep、Gut等学术期刊审稿人。担任《细胞生物学》、《生命的化学》等期刊编委、中国抗癌协会肿瘤胃肠病学等多个专业委员会委员。\n代表性工作揭示了Hippo信号通路调控消化道肿瘤发生及免疫应答的机制与功能，发现了一批疾病诊断标志物和先导药物，推动我国胃癌基础研究走向国际前沿，迄今以通讯作者（含共同）在Nature Immunology (x2)、Cancer Cell (x2)、Journal Clinical Investigation (x2)、Journal Experimental Medicine (x2)、Nature Communications (x3)、EMBO Journal (x3)、Cell Research (x2)、Protein Cell (x2)、Cell Reports、Journal Hepatology 、Cancer Research、Cell Discovery等国际学术期刊发表论文百余篇，被Cell、Nature、F1000Prime等评价和推荐，并获一系列发明专利授权。\n授课情况\n《癌生物学》、《现代生物学基础与前沿Ⅱ-遗传和发育生物学》\n招生专业\n遗传学、细胞生物学、生化与分子生物学\n科研项目\n主持在研或已结题的项目包括：国家自然科学基金委杰出青年项目、原创探索项目、重点项目、香港区域联合项目、面上项目等；国家科技部高技术中心发育代谢重点研发计划（组织器官生长与尺寸控制的信号基础与感知调控专项）；上海市重点项目；多个转化医学研究横向项目。\n代表性论文(1-102)\n1. Zhu ZH, Ding R, Yu W, Liu Y, Zhou ZC, Liu CY: YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer. Cell Death Differ 2025, 32(5):911-925.\n2. Zhang WH, Wang SL, Zhang H, Meng Y, Jiao S, An LW, Zhou ZC: Modeling human gastric cancers in immunocompetent mice. Cancer Biology & Medicine 2024, 21(7):553-570.\n3. Wen FP, Han Y, Zhang H, Zhao ZT, Wang WJ, Chen F, Qin WM, Ju JY, An LW, Meng Y et al: Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression. Nature Communications 2024, 15(1).\n4. Tang Y, Chen F, Fang GM, Zhang H, Zhang YN, Zhu HY, Zhang XR, Han Y, Cao ZF, Guo FH et al: A cofactor-induced repressive type of transcription factor condensation can be induced by synthetic peptides to suppress tumorigenesis. Embo Journal 2024, 43(22):5586-5612.\n5. Nie P, Cao Z, Yu R, Dong C, Zhang W, Meng Y, Zhang H, Pan Y, Tong Z, Jiang X et al: Targeting p97–Npl4 interaction inhibits tumor Treg cell development to enhance tumor immunity. Nature immunology 2024, 25(9):1623-1636.\n6. Ju JY, Zhang H, Lin MB, Yan ZF, An LW, Cao ZF, Geng DD, Yue JW, Tang Y, Tian LY et al: The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer. Journal of Clinical Investigation 2024, 134(10).\n7. Cao ZF, Hou Y, Zhao ZT, Zhang H, Tian LY, Zhang YM, Dong C, Guo FH, Tan LJ, Han Y et al: Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity. Journal of Biological Chemistry 2024, 300(6).\n8. Zhang JL, Chen BN, Li H, Wang YF, Liu XL, Wong KY, Chan WN, Chan AKY, Cheung AHK, Leung KT et al: Cancer-associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2-IGF1R and Hippo-YAP1 signaling pathways. Journal of Pathology 2023, 259(2):205-219.\n9. Nie PP, Zhang WH, Meng Y, Lin MB, Guo FH, Zhang H, Tong ZZ, Wang M, Chen F, An LW et al: A YAP/TAZ-CD54 axis is required for CXCR2 CD44 tumor-specific neutrophils to suppress gastric cancer. Protein & cell 2023, 14(7):515-533.\n10. Meng Y, Zhao QD, Sang Y, Liao JP, Ye F, Qu SP, Nie PP, An LW, Zhang WH, Jiao S et al: GPNMB Gal-3 hepatic parenchymal cells promote immunosuppression and hepatocellular carcinogenesis. Embo Journal 2023, 42(24):e114060.\n11. Meng Y, Ye F, Nie PP, Zhao QD, An LW, Wang WJ, Qu SP, Shen ZM, Cao ZF, Zhang XB et al: Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. Journal of Hepatology 2023, 79(6):1435-1449.\n12. Li YH, Peng JY, Xia YX, Pan CY, Li Y, Gu WJ, Wang J, Wang CX, Wang Y, Song JW et al: Sufu limits sepsis-induced lung inflammation via regulating phase separation of TRAF6. Theranostics 2023, 13(11):3761-3780.\n13. Jiao S, Li CC, Guo FH, Zhang JJ, Zhang H, Cao ZF, Wang WJ, Bu WB, Lin MB, Lü JH et al: SUN1/2 controls macrophage polarization via modulating nuclear size and stiffness. Nature Communications 2023, 14(1):6416.\n14. Cao ZF, An LW, Han Y, Jiao S, Zhou ZC: The Hippo signaling pathway in gastric cancer. Acta biochimica et biophysica Sinica 2023, 55(6):893-903.\n15. Cao JJ, Ji LL, Zhan YX, Shao X, Xu PC, Wu BT, Chen P, Cheng LY, Zhuang XB, Ou Y et al: MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages. Cellular & molecular immunology 2023, 20(12):1413-1427.\n16. Wei W, Tang XF, Jiang N, Ni C, He H, Sun SF, Yu M, Yu CY, Qiu MD, Yan D et al: Chromatin remodeler Znhit1 controls bone morphogenetic protein signaling in embryonic lung tissue branching. Journal of Biological Chemistry 2022, 298(10):102490.\n17. Wang YF, Chen HR, Liu WX, Yan H, Zhang YH, Cheung AHK, Zhang JL, Chen BA, Liang L, Zhou ZC et al: MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target. Theranostics 2022, 12(15):6509-6526.\n18. Guo YG, Zhu ZH, Huang ZY, Cui L, Yu W, Hong WJ, Zhou ZC, Du P, Liu CY: CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis. Nature Communications 2022, 13(1):4995.\n19. Chen K, Tang Y, Wu M, Wan XC, Zhang YN, Chen XX, Yu FQ, Cui ZH, Ma JM, Zhou ZC et al: Head-to-Tail Cross-Linking to Generate Bicyclic Helical Peptides with Enhanced Helicity and Proteolytic Stability. Organic Letters 2022, 24(1):53-57.\n20. An LW, Cao ZF, Nie PP, Zhang H, Tong ZZ, Chen F, Tang Y, Han Y, Wang WJ, Zhao ZT et al: Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers. Journal of Clinical Investigation 2022, 132(9).\n21. 张慧, 聂平平, 焦石, 周兆才: 胃肠道肿瘤发生及免疫应答的细胞信号机制. 生命的化学 2022, 42(05):882-891.\n22. 曹智发, 汤扬, 聂平平, 韩毅, 周兆才, 安利伟: STRIPAK复合物与肿瘤发生. 中国细胞生物学学报 2022, 44(04):758-769.\n23. Zhou ZC, Yuan ZQ, Hong WJ, Wang WQ: Editorial: A Hippo's View: Fro"